Epigenetic silencing by hypermethylation of CpGs represents a mechanism of inactivation of tumor suppressors. Here we report on the cloning of a novel candidate tumor suppressor gene TCEAL7 inactivated by methylation in ovarian cancer. TCEAL codes for a 1.35 kb transcript that was previously reported to be downregulated in ovarian cancer by cDNA microarray and suppression subtraction cDNA (SSH) analyses. This report focuses on the elucidation of mechanisms associated with TCEAL7 downregulation. Expression of TCEAL7 is downregulated in a majority of ovarian tumors and cancer cell lines but induced by 5-aza-2 0 -deoxycytidine treatment in a dosedependant manner, implicating methylation as a mechanism of TCEAL7 inactivation. Sequence analyses of bisufite-modified genomic DNA from somatic cell hybrids with either the active or the inactive human X chromosome reveal that TCEAL7 is subjected to X chromosome inactivation. Loss of TCEAL7 expression in primary tumors and cell lines correlates with methylation of a CpG site within the promoter. In vitro methylation of the CpG site suppresses promoter activity whereas selective demethylation of the SmaI site attenuates the suppression. Finally, re-expression of TCEAL7 in cancer cell lines induces cell death and reduces colony formation efficiency. These data implicate TCEAL7 as a cell death regulatory protein that is frequently inactivated in ovarian cancers, and suggest that it may function as a tumor suppressor.
Introduction
In the United States, 27 000 women were diagnosed with ovarian cancer and approximately 14 000 were expected to succumb to the disease in 2004 (Jemal et al., 2004) . Such high mortality rates are the direct result of a majority of patients presenting with advanced disease, and underscore the need for the development of better tools for the screening, diagnosis, and treatment of ovarian cancer. Increased understanding of genetic alterations associated with and the functional consequences of such alterations in cancer would provide the groundwork for development of early detection markers, novel therapeutic targets, and better management of ovarian cancer. Toward this goal, we performed cDNA microarray and suppression subtraction hybridization analyses to identify early genetic alterations associated with ovarian cancer. These studies resulted in the identification of several genes that are differentially expressed in ovarian cancer (Shridhar et al., 2001b (Shridhar et al., , 2002 . Based on our initial screen of several of these differentially expressed genes, we selected a novel proapoptotic protein for further analysis, and it is the focus of this study.
In the present manuscript, we describe the molecular cloning of a monoallelically expressed novel proapoptotic nuclear protein, TCEAL7, that shares amino-acid sequence homology with transcription elongation factor A-like 1 (TCEAL1/p21/SIIR/pp21) and pp21 homolog (WBP5/TCEAL6). TCEAL7 also shares sequence homology with p75 NTR -associated death executor (NADE). All four of these genes map to a region of X chromosome inactivation (Xq22.1-22.2). pp21 homolog and NADE map B24 and B42 kb telomeric to TCEAL7, respectively. The function of pp21 homolog is not yet characterized. However, its homolog, pp21, also on the X chromosome has been shown to suppress RSV LTR (Rous sarcoma virus long-terminal repeat) promoter activity and inhibit RSV LTR-mediated transformation in chicken embryo fibroblast (Yeh and Shatkin, 1994) . The transcriptional repression of RSV LTR by pp21 requires an interaction with a cis-acting promoter element because pp21 does not bind DNA directly (Yeh and Shatkin, 1995) . NADE is a proapoptotic protein involved in modulating apoptosis mediated by the low-affinity neurotropin receptor (Mukai et al., 2002) . It contains a leucine-rich nuclear export signal (NES) in the carboxyl terminus, and its cytosolic localization is required for mediating p75NTR-induced apoptosis. It also contains a domain required for induction of apoptosis, a regulatory domain, a selfassociation domain, and a 14-3-3 interacting domain (Mukai et al., 2002) .
We have made several original observations regarding the potential role of TCEAL7 inactivation in ovarian tumorigenesis. First, we observed that the expression of TCEAL7 is lost in >90% of primary ovarian tumors and cell lines. Second, we have shown that the loss of expression of TCEAL7 in primary tumors and cell lines is due to methylation of the active expressed allele. Finally, forced expression of TCEAL7 in deficient cell lines induces cell death and suppresses colony formation efficiency. These observations suggest that loss of expression of TCEAL7 may promote the survival of cancer cells, leading to the development of ovarian cancer.
Results

Isolation and characterization of a novel cDNA
We identified an EST (AJ297363) within the Unigene cluster -Hs.21861 as a downregulated gene in three of four suppression subtraction libraries of primary ovarian tumors subtracted against normal ovarian epithelial cell brushings (OSEs) (Shridhar et al., 2002) . cDNA microarray analysis of early-and late-stage ovarian tumors versus normal OSEs also revealed that this EST was at least fivefold downregulated in all 14 tumors analysed (Shridhar et al., 2001b) .
Comparative sequence analysis of this fragment using the BLAST alignment revealed that the 306 bp fragment showed considerable sequence alignment with several ESTs. The homologous ESTs were assembled into a contig with the use of Sequencher 3 (Gene Codes Corp) software. The entire cDNA contig was sequenced twice with overlapping primers. The integrity of the full-length cDNA obtained by this electronic walking was confirmed by PCR analysis using PCR primers flanking each junction between EST clones. The assembled gene revealed that it is made up of three exons with the open reading frame (ORF) residing within exon 3 (Figure 1a ). Exons 1, 2, and 3 are 109, 118, and 949 bp long, respectively. Introns 1 and 2 are 618 and 336 bp long, respectively, and follow the GT:AG rule. The ORF codes for a 100-amino-acid-long protein ( Figure 1c ) and contains a coiled-coil domain (Figure 1c , highlighted in black and Figure 1b) , and the initiation codon is preceded by an in-frame stop codon within a strong Kozak context (Kozak, 1996) (Figure 1b ).
Similarity alignment of TCEAL7 to other proteins
To identify potential domains of this novel gene, a Blastp search was performed (Altschul et al., 1997) . The search revealed sequence similarity to brain-expressed (Bex) proteins, Bex1-3 (Figure 2a ). The Bex proteins belong to a small family of genes comprised of bex1 (Faria et al., 1998) , bex2 and bex3 (Rapp et al., 1990; Mukai et al., 2000) . We therefore named the newly identified gene, mapping between bex2, and bex3 on X22.1-22.2, as bex4. All four bex genes are closely linked on the X chromosome and are predominantly expressed in the brain. However, recently, HUGO renamed bex1 as TCEAL8 and bex4 as TCEAL7. For this reason, we will refer to bex4 as TCEAL7. TCEAL8 is ubiquitously expressed (Williams et al., 2002; Yang et al., 2002) . Although tissue distribution of bex3 is not well characterized, it is also known as p75 neurotropin receptor (p75 NTR )-associated death executor (NADE) and shown to interact with low-affinity receptor p75 NTR in an NGF-dependent manner (Mukai et al., 2000 (Mukai et al., , 2002 . TCEAL7 and NADE show 50% sequence similarity within apoptosis-inducing domain and 77% sequence similarity with regulatory domain (Figure 2b ).
Expression in ovarian carcinoma cell lines and primary tumors
To validate the results obtained by microarray and SSH analyses, TCEAL7 expression was tested in seven ovarian cancer cell lines and in 26 primary ovarian tumors by semiquantitative RT-PCR. Short-term cultures of normal ovarian epithelial cells (OSE) and epithelial cell brushings (B) from patients without cancer served as positive controls. TCEAL7 expression is not detectable in any of the ovarian cancer cell lines ( Figure 3a ) and in majority of primary tumors, while short-term culture ovarian surface epithelial cells (OSE, sample #27) and immortalized OSE(tsT) (sample #28) express TCEAL7 (Figure 3b ). Expression of TCEAL7 in short-term culture ovarian surface epithelial cells is further confirmed by Western blot using polyclonal antibodies against TCEAL7 (Figure 3c ). Quantitative RT-PCR analysis using Light Cycler Assay indicates that TCEAL7 is significantly downregulated in ovarian tumors of different histologies (Figure 3d ).
Mechanism of TCEAL7 inactivation
To investigate the mechanisms of TCEAL7 inactivation, several approaches were taken. First, 20 pairs of matched normal and primary ovarian tumors were analysed for loss of heterozygosity (LOH) with two different microsatellite markers within the TCEAL7 gene. LOH analysis revealed 25% (5/20) of tumors showed LOH in this region of the chromosome (data not shown). Second, mutational analysis of all three exons in 96 primary ovarian tumors showed no tumorspecific changes (data not shown). In order to determine whether methylation controlled TCEAL7 expression, OV207 cells were treated with various concentrations of methyltransferase inhibitor, 5-aza-2 0 -deoxycytidine (5-aza-dC) (Saitoh et al., 1995; Persengiev and Kilpatrick, 1997) . Figure 4a shows a dose-dependent increase in TCEAL7 expression in OV207 following 5-aza-dC treatment. Consistent with this finding, genomic sequence analysis indicated 26 CpG sites around four SmaI sites in the promoter, exon 1, and intron 1 (Figure 4b ). Primers flanking these SmaI sites were selected to amplify and sequence the bisulfite-modified DNA. Amplicon 1 contains SmaI site I at 738 bases upstream of exon 1 and includes two CpG sites. Amplicon 2 contains SmaI site II within exon 1 and site III at 126 bases 3 0 of exon 1 and includes five other CpG sites. Amplicon 3 contains SmaI site IV in intron 1 at 286 bases 3 0 to site 3 and includes six additional CpG sites. Therefore, a total of 16 CpG sites were analysed.
Five CpG sites between amplicons 1 and 2 and between 3 and 4 were not included in the analysis. In order to distinguish unmodified from modified DNA, PCR was performed on bisulfite-modified DNA as previously described (Herman et al., 1996; Shridhar et al., 2001a) . Amplicons were gel purified and sequenced to determine the overall methylation status of 16 CpG sites. Figure 4b ) are resistant to bisulfite modification and remain as C's, whereas unmethylated C's are converted to T's ( Figure 4b ). Since TCEAL7 maps to a region of X chromosome inactivation (Brown and Kay, 1999) , we included somatic cell hybrids containing either active X [Y162.11C] (Xa) and inactive X [Y162.5E1T2] (Xi) as positive and negative controls in these analyses. Methylation analyses of bisulfite-modified DNAs from Xa and Xi cell lines showed differential methylation at sites II, III, and IV between two hybrid cell lines ( Figure 4c , first & second row). However, CpG in SmaI site I was methylated in both the active and the inactive X. RT-PCR analysis of TCEAL7 expression in these hybridomas carrying either Xa or Xi chromosome showed loss of TCEAL7 expression in both lines (data not shown). These results suggest that methylation at SmaI site I might play a critical role in controlling the expression of TCEAL7.
Methylation of CpG in SmaI site I controls TCEAL7 expression in the somatic cell hybrid containing the active X In order to determine if methylation of CpG site I is inactivating TCEAL7 expression in Xa-containing cell line, cells were treated with various concentrations of 5-aza-dC. A dose-dependent increase in TCEAL7 expression in this cell line was observed following 5-aza-dC treatment ( Figure 5a ). Subsequent analysis of bisulfitemodified DNA from 5-aza-dC-treated Xa cells revealed demethylation of site 1, concomitant with induction of TCEAL7 transcript (Figure 5b ). These data suggest that site I methylation may control TCEAL7 expression in this cell line. In order to rule out the possibility of histone deacetylation as a mechanism of TCEAL7 transcriptional inactivation, Xa-containing cells were treated with various concentrations of the histone deacetylase inhibitor, trichostatin A. Trichostatin A did not affect the transcription of TCEAL7 in these cells ( Figure 5c ). To demonstrate that methylation of CpG in SmaI site I influences the promoter activities in vitro, amplicon 1 was subcloned into pGL3 reporter plasmid, and the CpG site I was mutated to ApG. Both plasmids were subjected to bisulfite modification, and modified plasmids were transfected into HeLa cells to determine the promoter activity of these two plasmids. As shown in Figure 5d , nonmutated plasmid showed diminished promoter activity compared to the mutated plasmid, suggesting that methylation of CpG site I in nonmutated plasmid suppressed promoter activity and that prevention of CpG site methylation by site-directed mutagenesis prevented this suppression of promoter activity.
Methylation of CpG in SmaI site I reflects TCEAL7 inactivation in primary ovarian tumors
Since our data indicate using both in vitro promoter assay and methylation analysis that methylation at site I controls TCEAL7 transcription in the Xa cell line, we tested whether methylation at site I in primary tumors and cell lines is associated with loss of TCEAL7 expression. Methylation status of 16 CpG sites was determined by genomic sequencing of bisulfite-modified Figure 6b . Consistent with the hypothesis that methylation of site I controls TCEAL7 expression, biallelic methylation at site I in these samples reflects loss of TCEAL7 expression as evidenced by semiquantitative RT-PCR analysis (Table 1, e.g. 4, 13, 206, 208, 402, 414, 34, 98, 121, 183, 235, 259, 339 , and cancer cell lines). However, there were a few exceptions (Table 1, #45, 183, and 235) . In these samples, TCEAL7 expression was lost although site I was hemimethylated, suggesting the involvement of other mechanisms in inactivation of TCEAL7.
To determine if LOH could also be responsible for inactivation of TCEAL7, we analysed both LOH and methylation in a subset of tumors. Majority of tumors with CpG site I methylation did not have LOH (Table 1 , tumors highlighted in bold), suggesting that both mechanisms are not required to completely inactivate TCEAL7 expression. In addition, there was no correlation between the methylation status and age of patient. Together, these data are consistent with the hypothesis that TCEAL7 is monoallelically expressed and therefore requires a tumor-related epigenetic silencing to inactivate the active allele.
Forced expression of TCEAL7 induces apoptosis
Since TCEAL7 shares domain homology with Bex3/ NADE (Figure 2a) , a known mediator of p75 NTR -induced apoptosis, the apoptotic potential of TCEAL7 was tested in ovarian cancer cells. At 48 h after transfection, morphological analysis of SKOV3 transiently transfected with TCEAL7-GFP fusion construct showed apoptotic morphology, such as cytoplasmic shrinkage and membrane blebbing (Figure 7a , upper panels), whereas vector-transfected cells (Figure 7a , lower panels) displayed normal morphology. To confirm that TCEAL7-transfected cells were undergoing apoptosis, nuclear morphologic analysis with Hoechst stain was performed on these cells. As shown in Figure 7a , expression of TCEAL7 produces pyknotic nuclei (indicated by arrows), while expression of GFP does not produce such phenotype. Quantitation of apoptotic cells indicated significantly higher percentage of apoptosis in TCEAL7-transfected cells compared to vector GFPtransfected cells (Figure 7b ). Consistent with these results, forced expression of TCEAL7 suppressed clonogenic survival of OV202 ovarian cancer cells (Figure 7c ).
Discussion
DNA methylation of cytosine residues in CpGs is associated with transcriptional silencing and plays an important role in X chromosome inactivation and gene imprinting during mammalian development (Li et al., 1992; Jaenisch and Bird, 2003) and in epigenetic silencing of tumor suppressors during carcinogenesis (Jones and Laird, 1999) . Epigenetic silencing of tumor suppressors is well documented in cancer, and may represent a mechanism in Knudson's two-hit hypothesis. Epigenetic inactivation of tumor suppressors, such as the von Hippel-Lindau syndrome (VHL), breast cancer, type 1 (BRCA1), retinoblastoma (RB1), cyclin-dependent kinase inhibitor 2A and 2B (CDKN2A and 2B), mutL homolog 1 (MLH1), and adenomatous polyposis of the colon (APC), has been well documented in carcinogenesis (Jones and Laird, 1999; Baylin and Herman, 2000; Baylin and Bestor, 2002; Esteller et al., 2002; Jones and Baylin, 2002; Laird, 2003) . Although homozygous or heterozygous deletions and mutations represent classical mechanisms of inactivation of tumor suppressors, epigenetic silencing by hypermethylation has also gained widespread acceptance as an additional mechanism of inactivation (Jones and Baylin, 2002) . In fact, close to 50% of genes associated with familial forms of cancer are subjected to epigenetic silencing in various sporadic forms of cancer, in addition to a growing list of candidate tumor suppressor genes that are silenced by hypermethylation (Jones and Baylin, 2002) . These reports highlight the significance of aberrant hypermethylation in carcinogenesis.
We believe that TCEAL7 is an excellent candidate tumor suppressor selectively inactivated in ovarian cancer. Expression of pp21 homolog, a related gene mapping 24 kb telomeric to TCEAL7, is not lost in ovarian cell lines tested. Expression of bex3/NADE, another related gene mapping 43 kb centromeric to TCEAL7, showed reduced expression in only two of Epigenetic silencing of TCEAL7 J Chien et al seven ovarian cancer cell lines. TCEAL8, located 256 kb telomeric to TCEAL7, is lost in only three of seven ovarian cancer cell lines (data not shown). Consequently, of the three highly identical genes in Xq22.1-22.2, only TCEAL7 showed complete loss of expression in all the tested cell lines. Although these three genes mapping to the region could potentially be inactivation targets, we believe that TCEAL7 is the most likely target gene since expression of TCEAL7 is lost in >90% of primary ovarian tumors and 100% of the cell lines compared to other genes in this region.
Presumably, the presence of a tumor suppressor gene on the X chromosome would imply that males with only one X chromosome would be more prone to tumorigenesis than females with two X chromosomes. However, since TCEAL7 is subjected to X chromosome inactivation and normally expressed from one allele, lack of second allele in male would not be significant.
The presence of a putative tumor suppressor gene on the X chromosome where one allele is inactivated as a result of X inactivation, a single hit in the active allele, would be sufficient to inactivate the gene. Under such a scenario, LOH, mutation, or methylation of the active allele could contribute to the loss of function of the tumor suppressor gene. Since we could not detect any mutation in 96 ovarian tumors we analysed by DHPLC, mutational inactivation may not be the predominant mechanism in the silencing of TCEAL7 in ovarian Filled and unfilled circles represent methylated and unmethylated alleles, respectively. A circle with a line across represents hemimethylation. Expression X1.5-fold over OSE (++++), between 1.1 and 0.9-fold (++); p0.5 (+); no expression (-), not determined (ND); positive LOH (+LOH); negative LOH (ÀLOH). Samples used in RT-PCR ( Figure 6b ) and LOH analyses are highlighted in bold cancer. Analysis of LOH and TCEAL7 expression showed only one tumor with LOH with corresponding loss of TCEAL7 (Table 1, #208) . In tumor #97, TCEAL7 expression was detected even though the tumor showed LOH, suggesting deletion of the inactive allele in this tumor. These data suggest that LOH may not be the main mechanism responsible for the inactivation of TCEAL7 in ovarian tumors. However, based on the fact that the TCEAL7 expression is induced by demethylation on 5-aza-2 0 -deoxycytidine treatment, it seems most likely that methylation is the mechanism by which TCEAL7 is inactivated in a majority of primary ovarian tumors and cell lines. Consistent with this hypothesis, majority of cell lines and tumors with loss of TCEAL7 expression showed hypermethylation of some specific CpG sites in the promoter region. These data suggest that epigenetic silencing as a major mechanism in TCEAL7 inactivation. Emerging evidence indicates that epigenetic silencing by methylation of tumor suppressor genes is a common mechanism leading to loss of function of the gene.
The fact that TCEAL7 expression is epigenetically silenced in ovarian cancer might be of clinical significance because unlike mutation where DNA information is irreversibly changed, epigenetic modification can be reversed by DNA methyl transferase inhibitors or histone-modifying agents (Teodoridis et al., 2004) . With the emerging role of the use of small molecule inhibitors that modify the enzyme activities of DNA methyl transferases and histone deacetylases in 'epigenetic therapies' (Esteller, 2005) , TCEAL7 could serve as a potential target of epigenetic therapy. It is suggested that re-expression of silenced apoptotic genes by epigenetic therapy might re-sensitize drug-resistant cancer cells to conventional chemotherapy (Balch et al., 2004) . In that sense, re-activation of TCEAL7 in chemoresistant ovarian cancer might be of clinical relevance. Finally, due to its widespread loss in ovarian cancer, TCEAL7 may potentially be used as an epigenetic marker for detection of ovarian cancers at earlier stages.
Although recent data on the methylation status of several genes implicate a spreading of methylation and an overall increase in the frequency of methylated CpGs in the tumor cell lines and primary ovarian tumors, our data indicate that specific sites within the promoter as a target of methylation. Site-specific methylation in the BRCA1 regulatory region, specifically at the cyclic AMP response element, was observed in breast and ovarian tumors (Mancini et al., 1998) . Site-specific methylation of Wilms tumor suppressor gene in rat mesotheliomas (Kleymenova et al., 1998) , and in TIMP3 gene (Pennie et al., 1999) have been reported. More recently, specific methylation at À253 and À251 nt of the hMLH1 gene was observed in two of 60 primary gastric carcinomas, but not in the corresponding mucosa or in normal gastric samples (Deng et al., 2003) . Consistent with these Epigenetic silencing of TCEAL7 J Chien et al reports, our analysis also indicates site-specific methylation may control TCEAL7 expression. This conclusion is further supported by our promoter analysis where site-specific mutation that prevents methylation at this site also prevented the epigenetic silencing of the promoter.
Although there is general consensus that transcriptional activities of X-linked genes are maintained in the somatic cell hybrids, there are exceptions to this rule (Brown and Robinson, 1997) . Sequence analysis of genomic DNA from hybrids containing active X did not show any deletion or mutation of the primer annealing sites. While the reasons for this selective inactivation are not known, further analysis indicated that methylation of TCEAL7 at CpG sites 1 and 2 was the mechanism of inactivation, as treatment with 5-aza-dC caused demethylation at this site and expression of TCEAL7 in this cell line. Although demethylation of other genes involved in the transcription of TCEAL7 could account for this induction, the fact that in vitro methylation of the promoter suppresses the promoter activity lends support to direct activation of the promoter on demethylation. Inactivation of TCEAL7 during somatic cell hybrid generation appeared to be specific, since two flanking genes, namely pp21 homolog and bex3/NADE, were expressed by active X. Evidence for age-related methylation has been documented for tumor suppressor and tumor-related genes and in women with increasing age (Waki et al., 2003; Hatakeyama et al., 2004) . We did not see a strong correlation to increasing age as a factor in biallelic methylation pattern seen at sites 1, 2, and 4 as evidenced by lack of biallelic methylation at site 3 in a majority of samples (17/24 primary tumor samples).
We find that re-expression of TCEAL7 induces apoptosis, suggesting that the loss of TCEAL7 is not a random event in carcinogenesis, but a selected event that favors the survival of cancer cells. TCEAL7 belongs to the family of brain-expressed proteins that includes the p75 NTR -associated death executor (NADE/Bex3). NADE/Bex3 has been shown to mediate apoptosis induced by p75 NTR (Mukai et al., 2000) . These data suggest that loss of function of the proapoptotic protein TCEAL7 in cancer cells may confer them survival advantage and may promote tumorigenesis. However, it should be noted that apoptosis associated with reexpression of TCEAL7 could be the result of overexpression, since TCEAL7 is monoallelically expressed in normal ovarian epithelial cells without detrimental effect to the cells. Functional analysis elucidating TCEAL7 interacting proteins will shed more light on the role of this nuclear protein plays in apoptosis regulation.
Materials and methods
Cell culture
Five of eight ovarian carcinoma cell lines (OV 167, OV 177, OV 202, OV 207, and OV 266) were low-passage primary lines established at the Mayo Clinic (Conover et al., 1998) , while OVCAR-5 and SKOV-3 were from American Type Culture Collection (Manassas, VA, USA). All cells were grown according to the providers' recommendations.
Strategy for cloning the gene
BLAST search of the isolated sequence identified several homologous ESTs in the dbEST. The homologous ESTs were assembled into a contig with the use of Sequencher 3 (Gene Codes Corp, Ann Arbor, MI, USA) software. The integrity of the full-length cDNA obtained by this electronic walking was confirmed by PCR analysis using PCR primers flanking each junction between EST clones. The entire cDNA contig was sequenced twice with overlapping primers.
Immunoblotting
Western blot analysis was performed using whole-cell lysates from ovarian cell lines. Polyclonal antibodies against TCEAL7 were generated by injecting two rabbits with the recombinant full-length TCEAL7 protein purified from bacteria using pGEX expression system (Novagen, San Diego, CA, USA).
Light Cycler Assay
Using TCEAL7-F (5 0 -AAAAACCCTGCAAAGAAAAC GAA-3 0 ) and TCEAL7-R (5 0 -CCATACGGGCGTTTTTC CT-3 0 ) plus RPS9F (5 0 -TCGCAAAACTTATGTGACCC-3 0 ) and RPS9R (5 0 -TCCAGCACCCCCAATC-3 0 ) primers, duplex PCR amplification was carried out with Light-Cycler (Roche, Indianapolis, IN, USA) in the presence of SYBR-Green dye according to the following conditions: 1 min at 951C for initial denaturation, followed by 40 cycles at 951C (10 s), 581C (15 s), and 721C (20 s), followed by the measurement of fluorescence at the end of each cycle. After the 40th cycle, melting curve analyses were performed with Light-Cycler software by denaturing the sample at 951C, rapidly cooling down to 651C for 15 s, and measuring the fluorescence as the sample temperature was gradually raised to 951C in steps of 0.11C/s. Each run included a negative control and a known RPS9 control.
Assessment of methylation control
The somatic cell hybrid [Y162.11C] containing the active X (Xa) and OV 207 cell lines were treated with varying concentrations of 5-aza-2 0 -dc ranging from 1 to 5 mM the day after plating. After a 48 h exposure to 5-aza-2 0 -dc, the cells were harvested in Trizol (Gibco/Life Technologies, Rockville, MD, USA) for RNA extraction.
Genomic sequencing of bisulfite-modified DNA
The methylation status of TCEAL7 was determined by genomic sequencing of bisulfite-modified DNA as described previously (Shridhar et al., 2001a) 
Semiquantitative RT-PCR
A 50-100 ng portion of reverse-transcribed cDNA was used in a multiplex reaction with TCEAL7-99F: 5 0 -GCA GGA AAC AAC AAC AAC AT-3 0 and reverse primer TCEAL7-523R: 5 0 -AAG TGC AGA CAA ACA GAA AGC AGT GG-3 0 and GAPDH forward (5 0 -ACC ACA GTC CAT GCC ATC AC-3 0 ) and reverse primers (5 0 -TCC ACC ACC CTG TTG CTT GTA-3 0 ). The primers for pp21 homolog and Bex3/NADE are as follows: pp21ORF F 5 0 -GAA GGA AGA GAG GTA GAC AG-3 0 , pp21ORF R 5 0 -GGG GTA AGG ATG GTT TCG AT-3 0 , Bex3/NADE F 5 0 -GTC TCT CTC CTT GCC TTT GT-3 0 , and Bex3/NADE R 5 0 -ATG GCA GGA GTC AAG GCA TA-3 0 . The PCR reaction mixes contained 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 400 mM of each primer for TCEAL7 and 50 mM for the GAPDH primers, and 0.5 U of Taq polymerase (Qiagen, Valencia, CA, USA) in a 12.5 ml reaction volume. The conditions for amplification were 941C for 3 min, and then 29 cycles of 941C for 30 s, 581C for 30 s, and 721C for 30 s in a Perkin-Elmer-Cetus 9600 Gene-Amp PCR system. The products of the reaction were resolved on a 1.6% agarose gel. Band intensities were quantified using the Gel Doc 1000 photodocumentation system (Bio-Rad, Hercules, CA, USA) and its associated software and normalized with GAPDH controls.
Plasmid constructs
The coding region of TCEAL7 was amplified by PCR using primers (5 0 ) GCA GGA AAC AAC AAC AAC ATC and (3 0 ) TTA AAT GGG ATA AGG GAC GGT-3 0 and cloned into pcDNA3/GFP-CT TOPO cloning vector from Invitrogen following the manufacturer's recommendations.
Promoter constructs
To investigate whether SmaI site I methylation suppresses TCEAL7 promoter activity, an 882 bp fragment containing 12 CpG sites including the SmaI sites I and II was cloned into XhoI and HindIII sites in pGL3 vector. Primers used for promoter construct were as follows: (a)-F/R, 5 0 -CCGC TCGAG GACTTACAGTTGCGATCTGG-3 0 /5-CCCAAGC TT CCTCCTTCCTGTCTGTATCC-3 0 . Constructs carrying single-site mutation of sites I and II were generated by mutating CCCGGG to CCAGGG so that it was no longer subjected to in vitro methylation.
Transient transfection and luciferase assays
HeLa cells were seeded at a density of 3 Â 10 5 /well in a six-well dish and grown to 60-70% confluence in complete growth media containing DMEM supplemented with 10% FBS. For each well, 2 mg of plasmid DNA and 0.01 mg of pRL-TK control vector (triplicate for each group) were cotransfected into cells with oligofectamine (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. After incubation for 24 h, cells were harvested, and luciferase activities were measured by using a Dual-Luciferase Report Assay System (Promega, Madison, WI, USA) in an Analytical Luminometer Monolight 2010 (PharMingen, San Diego, CA, USA) according to the manufacturer's instructions. Relative luciferase activities were calculated as the ratio of firefly/ Renilla luciferase.
In vitro methylation
In vitro methylation was carried out according to the methods described previously (Song et al., 2001) . Briefly, TCEAL7 promoter constructs containing wild-type or mutated SmaI I site I were incubated overnight with three units of SssI (CpG) methylase (New England Biolabs, Beverly, MA, USA) in the presence (methylated) or absence (mock-methylated) of 1 mM S-adenosylmethionine, as recommended by the manufacturer. After purification with a QIAquick Gel Extraction Kit (Qiagen) and quantitation of DNA at A260 nm, equal amounts (2 mg) of methylated reporter constructs were transiently transfected into HeLa cell lines, and luciferase activities were measured as described above (Song et al., 2001) . Individual reactions were monitored by digestion with SmaI restriction enzyme.
Densitometric analysis
Ethidium bromide-stained RT-PCR products of TCEAL7 and GAPDH were captured with GelDoc2000 system (Bio-Rad, Hercules, CA, USA), and densitometric analysis was performed using Quantity One software provided with GelDoc2000 system. TCEAL7 densitometric readings were normalized with that of corresponding GAPDH and expressed as fold increase or decrease compared to the TCEAL7 expression in OSE.
Assessment of cell viability
Cell viability was determined by examination of apoptotic morphology of nuclear staining with Hoechst 33258 as described previously.
Clonogenic assays
For clonogenic assays, flow-sorted vector GFP-and Bex4 GFP-containing cells (1000 cells/35 mm dish) were plated in triplicate, permitted to adhere overnight, and grown for 12-14 days to allow colonies to form. Cells were stained with Coomassie blue, digitally photographed, counted with Quantity One software (Bio-Rad), and expressed as % colonyforming efficiency.
